Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2024 | 820 | 1.280 |
Why?
|
| Neoplasms | 11 | 2024 | 3035 | 1.130 |
Why?
|
| Parents | 3 | 2022 | 1072 | 0.930 |
Why?
|
| Allopurinol | 4 | 2023 | 75 | 0.780 |
Why?
|
| Mercaptopurine | 4 | 2022 | 72 | 0.780 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2019 | 125 | 0.680 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 448 | 0.560 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 288 | 0.520 |
Why?
|
| Cephalosporins | 1 | 2017 | 143 | 0.510 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 722 | 0.490 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2023 | 198 | 0.460 |
Why?
|
| Physicians | 1 | 2021 | 640 | 0.450 |
Why?
|
| Renal Insufficiency | 1 | 2017 | 256 | 0.450 |
Why?
|
| Cranial Irradiation | 1 | 2012 | 72 | 0.370 |
Why?
|
| Fertility Preservation | 2 | 2023 | 58 | 0.360 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 2575 | 0.350 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 2022 | 14 | 0.330 |
Why?
|
| Hematologic Neoplasms | 2 | 2024 | 294 | 0.310 |
Why?
|
| Antioxidants | 1 | 2012 | 371 | 0.310 |
Why?
|
| Hospitalization | 6 | 2024 | 1921 | 0.300 |
Why?
|
| Cerebellar Neoplasms | 1 | 2012 | 461 | 0.280 |
Why?
|
| Adolescent | 20 | 2024 | 20610 | 0.270 |
Why?
|
| Medulloblastoma | 1 | 2012 | 571 | 0.270 |
Why?
|
| Health Status Disparities | 2 | 2021 | 252 | 0.270 |
Why?
|
| Child | 22 | 2024 | 25882 | 0.250 |
Why?
|
| Medical Oncology | 3 | 2023 | 247 | 0.250 |
Why?
|
| Mental Disorders | 1 | 2012 | 890 | 0.220 |
Why?
|
| Humans | 32 | 2024 | 133811 | 0.210 |
Why?
|
| Male | 19 | 2024 | 65939 | 0.200 |
Why?
|
| Thioguanine | 2 | 2022 | 22 | 0.200 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2022 | 19 | 0.200 |
Why?
|
| Boston | 2 | 2021 | 123 | 0.190 |
Why?
|
| Shock | 1 | 2023 | 99 | 0.190 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 4006 | 0.190 |
Why?
|
| Cancer Care Facilities | 1 | 2021 | 40 | 0.180 |
Why?
|
| Fever | 1 | 2024 | 312 | 0.180 |
Why?
|
| Down Syndrome | 1 | 2024 | 232 | 0.180 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 92 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 3506 | 0.170 |
Why?
|
| Female | 18 | 2024 | 71840 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 213 | 0.170 |
Why?
|
| Young Adult | 8 | 2024 | 9926 | 0.170 |
Why?
|
| Mycoses | 1 | 2021 | 117 | 0.160 |
Why?
|
| Maintenance Chemotherapy | 2 | 2023 | 21 | 0.160 |
Why?
|
| Trichosporonosis | 1 | 2018 | 8 | 0.150 |
Why?
|
| Invasive Fungal Infections | 1 | 2018 | 18 | 0.150 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2022 | 572 | 0.150 |
Why?
|
| Cross Infection | 1 | 2022 | 344 | 0.150 |
Why?
|
| Hypoglycemia | 2 | 2018 | 192 | 0.140 |
Why?
|
| Communication | 1 | 2022 | 542 | 0.140 |
Why?
|
| Opportunistic Infections | 1 | 2018 | 79 | 0.140 |
Why?
|
| Clinical Trials as Topic | 1 | 2023 | 1160 | 0.140 |
Why?
|
| Bacteremia | 1 | 2022 | 429 | 0.140 |
Why?
|
| Child, Preschool | 8 | 2024 | 14878 | 0.140 |
Why?
|
| Hospitals, Pediatric | 1 | 2022 | 795 | 0.140 |
Why?
|
| Cardiomyopathies | 1 | 2022 | 510 | 0.130 |
Why?
|
| Sepsis | 1 | 2022 | 522 | 0.130 |
Why?
|
| Fever of Unknown Origin | 1 | 2017 | 45 | 0.130 |
Why?
|
| Neutropenia | 2 | 2018 | 205 | 0.130 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 305 | 0.130 |
Why?
|
| Quality of Life | 2 | 2023 | 2161 | 0.130 |
Why?
|
| Methotrexate | 2 | 2018 | 355 | 0.120 |
Why?
|
| Aftercare | 1 | 2017 | 157 | 0.120 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 146 | 0.120 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 1853 | 0.120 |
Why?
|
| Heart Transplantation | 1 | 2022 | 887 | 0.120 |
Why?
|
| Registries | 1 | 2021 | 1586 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 411 | 0.110 |
Why?
|
| Guanine Nucleotides | 1 | 2013 | 14 | 0.110 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2013 | 35 | 0.110 |
Why?
|
| Biotransformation | 1 | 2013 | 56 | 0.110 |
Why?
|
| Thionucleotides | 1 | 2013 | 23 | 0.110 |
Why?
|
| Survivors | 2 | 2017 | 358 | 0.110 |
Why?
|
| Drug Evaluation | 1 | 2013 | 105 | 0.110 |
Why?
|
| Xanthine Oxidase | 1 | 2013 | 39 | 0.110 |
Why?
|
| Hyperbilirubinemia | 1 | 2013 | 42 | 0.110 |
Why?
|
| Methyltransferases | 1 | 2013 | 83 | 0.100 |
Why?
|
| Heart-Assist Devices | 1 | 2022 | 1098 | 0.100 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2012 | 33 | 0.100 |
Why?
|
| Glutathione Peroxidase | 1 | 2012 | 49 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 480 | 0.090 |
Why?
|
| Pediatrics | 1 | 2021 | 1221 | 0.090 |
Why?
|
| Infant | 6 | 2024 | 13246 | 0.090 |
Why?
|
| Glutathione Transferase | 1 | 2012 | 163 | 0.090 |
Why?
|
| Superoxide Dismutase | 1 | 2012 | 180 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 4 | 2001 | 874 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 1358 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 545 | 0.080 |
Why?
|
| Heart Failure | 1 | 2022 | 2428 | 0.070 |
Why?
|
| Neuropsychological Tests | 1 | 2012 | 992 | 0.070 |
Why?
|
| Adult | 6 | 2024 | 31823 | 0.070 |
Why?
|
| Antifungal Agents | 2 | 2021 | 305 | 0.070 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 681 | 0.060 |
Why?
|
| Age Factors | 3 | 2024 | 2987 | 0.060 |
Why?
|
| Genotype | 1 | 2012 | 2819 | 0.060 |
Why?
|
| Risk Factors | 4 | 2023 | 11166 | 0.060 |
Why?
|
| Blood Glucose Self-Monitoring | 3 | 2001 | 124 | 0.060 |
Why?
|
| Blood Glucose | 3 | 1999 | 1185 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 3739 | 0.060 |
Why?
|
| Patient Compliance | 2 | 2017 | 478 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 2948 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2023 | 5219 | 0.050 |
Why?
|
| Vomiting | 1 | 2023 | 110 | 0.050 |
Why?
|
| Semen | 1 | 2023 | 81 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2022 | 17577 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 211 | 0.050 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2023 | 198 | 0.050 |
Why?
|
| Levofloxacin | 1 | 2022 | 48 | 0.050 |
Why?
|
| Cryopreservation | 1 | 2021 | 76 | 0.040 |
Why?
|
| United States | 3 | 2023 | 11760 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 236 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2022 | 129 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2024 | 541 | 0.040 |
Why?
|
| Diarrhea | 1 | 2022 | 339 | 0.040 |
Why?
|
| Oocytes | 1 | 2021 | 302 | 0.040 |
Why?
|
| Voriconazole | 1 | 2018 | 34 | 0.040 |
Why?
|
| Lipopeptides | 1 | 2018 | 36 | 0.040 |
Why?
|
| Insulin | 2 | 2001 | 1245 | 0.040 |
Why?
|
| Echinocandins | 1 | 2018 | 44 | 0.040 |
Why?
|
| Amphotericin B | 1 | 2018 | 91 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 94 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 484 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2022 | 873 | 0.030 |
Why?
|
| Parent-Child Relations | 1 | 1999 | 254 | 0.030 |
Why?
|
| Disease Progression | 1 | 2023 | 2255 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1485 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1626 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2021 | 8632 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 5455 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1165 | 0.030 |
Why?
|
| Disease Management | 1 | 1998 | 565 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1736 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 1770 | 0.030 |
Why?
|
| Parenting | 1 | 1997 | 349 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2022 | 2730 | 0.020 |
Why?
|
| Middle Aged | 1 | 2012 | 29287 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2022 | 13114 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3416 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 3746 | 0.020 |
Why?
|
| Emergency Service, Hospital | 2 | 2001 | 1166 | 0.010 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2001 | 169 | 0.010 |
Why?
|
| Office Visits | 1 | 1999 | 78 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 1999 | 469 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2001 | 2303 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 1997 | 432 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2001 | 6602 | 0.010 |
Why?
|
| Time Factors | 1 | 1999 | 6554 | 0.000 |
Why?
|